Niccoló Bertini

@GiulioFrancoli1 @EAUYAU_RenalCa Great work! @MicheleAquilano 🤩💪🏻✌🏻

🧠 Can SBRT manage complex localized RCC? The YAU RCC Working Group tested it across PADUA risk groups. 💡 24/27 plans feasible—including high PADUA scores! 📊 Multicenter, multidisciplinary, and forward-looking. @EAUYAU_RenalCa #EMUC25

@GiulioFrancoli1 @ESTRO_RT @piet_ost We would like to inform you that your post has been published on OncoDaily. Thank you for sharing such valuable content. oncodaily.com/url/287260

☢️SBRT for kidney cancer: Wonderful joint ESTRO-ASTRO symposium with fantastic speakers. The future is really bright! ⚡ @DrStish @GiuliaMarvaso84 @StrijbosMichiel #estro25 @ESTRO_RT

Wonderful morning session about management of BCR in prostate cancer at ESTRO 2025. The complex shaping of a multidisciplinary issue!#ESTRO25 ,@ESTRO_RT,@piet_ost ,@Silke_Gillessen ,@ZilliThomas

Early results After stereotactic SRT on macroscopic prostate bed relapse (STARR-NCT05455736) suggested safety and effectiveness of this approach! #Estro25, @ESTRO_RT ,@NiccolBertini2

☢️ Use the link to see some insights about PERSIAN trial early results from ASCOGU25! @dicataldovanes1,@PietroGarlatti urotoday.com/video-lectures…

Upfront SBRT on top of standard of care Is the preferred treatment option for oligom+ CRPC. But it could be considered also as a viable approach for oligoPD. A subgroup analysis from ARTO trial. @NiccolBertini2,@dicataldovanes1,@PietroGarlatti rdcu.be/eayuq

Wonderful to be in San Francisco presenting early results of PERSIAN trial! #GU25 ,@PietroGarlatti ,@dicataldovanes1 ,@DrIacovelli ,@NiccolBertini2 ,@MicheleAquilano

@Flo_exp_RCC_25 It is an honor to participate in this amazing Expert meeting in a brilliant session! Thank to @Ric_Campi and my colleagues @GiulioFrancoli1 @dicataldovanes1 @NiccolBertini2 @MicheleAquilano

@you_trend ♥️

🔴 #BreakingNews‌ Ilaria #Bugetti (CSX) è stata eletta sindaca di #Prato. #MaratonaYouTrend